CAMN107A study of treatment-free remission in chronic myeloid leukemia in chronic phase CML-CP patients

Investigator: Swaminathan Iyer, MD

Study Coordinator: Erick Villarreal-Williams

Status: Open Not Enrolling Number: NCT01698905

Phone: 713.441.9775

IRB Number: Pro00009034


A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib (Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at least 3 years and have very small amount of leukemia cells remaining after the nilotinib (Tasigna) treatment will qualify for the study.
More to Explore